No abstract available.
Humans ; Hypercholesterolemia*

No abstract available.
Hypercholesterolemia* ; Lipoprotein-X* ; Lipoproteins*

No abstract available.
Humans ; Hypercholesterolemia* ; Lovastatin*

A 15-year-old, Indian, female child of a second-degree consanguineous marriage, presented with polymorphic yellowish-brown nodular cutaneous lesions over the dorsal aspect of both elbows, knees (Figure 1A) and buttocks (Figure 1B). These were suggestive of xanthoma tuberosum and were first noted at 4 years old. There were no spots over the eyelids, acanthosis, skin tags or tendon xanthomas. Arcus juvenilis was not noted. A bilateral carotid bruit was appreciated.
xanthoma ; familial ; hypercholesterolemia ; LDL

Hypercholesterolemia ; Cholesterol ; Stroke ; Coronary Disease

BACKGROUND: This study was designed to evaluate the clinical efficacy of pravastatin, HMG-CoA reductase inhibitor, in patients with hypercholesterolemia. Methods and RESULTS: Pravastatin 5 mg was administered twice daily for 12 weeks in twenty five patients(12 male, 13 female) with hypercholesterolemia(>240 mg/dl). Compared with pretreatment levels, pravastatin significantly decreased levels of total cholesterol(281+/-41mg/dl versus 218+/-31mg/dl) by 22% and LDL-cholesterol(199+/-46mg/dl versus 137+/-37mg/dl) by 31% with significantly decreased total-cholesterol/HDL-cholesterol ratio(7.1+/-3.0 versus 5.1+/-1.6) and LDL-cholesterol/HDL-cholesterol ratio(5.1+/-2.5 versus 3.3+/-1.4) (p<0.005, respectively). During pravastatin treatment, the level of Apo B(164+/-38mg/dl versus 123+/-20mg/dl) was decreased significantly by 24% with significantly decreased Apo B/Apo A-1 ratio(1.4+/-0.5 versus 1.0+/-0.3) (p<0.005, respectively). No serious side effects were found. CONCLUSIONS: Results from the present study show that pravastatin is an effective and well-tolerated cholesterol-lowering agent.
Humans ; Hypercholesterolemia* ; Male ; Oxidoreductases ; Pravastatin*

No abstract available.
Aged* ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors* ; Hypercholesterolemia*

We observed the levels of serum cholesterol, triglyceride and HDL-cholesterol in 28-hyperlipidemic patients after treatment with procetofene(Lipanthyl(R)), a new hypolipidemic agent. The results were as follows. 1. The hyperlipidemic patients were 7 cases of pure hypercholesterolemia, 12 cases of mixed hyperlipidemia and 9 cases of pure hypertriglyceridemia. 2. All the patients were treated with daily dose of 200 to 400mg, usually 300mg, and duration of more than 12 weeks. 3. The serum cholesterol decreased significantly at the rate of 29% in pure hypercholes terolemia and 29% in mixed hyperlipidemia after treatment for 12 weeks. 4. The serum triglyceride decreased significantly at the rate of 58% in mixed hyperlipidemia and 42% in pure hypertriglyceridemia after treatment for 12 weeks. 5. The serum HDL-cholesterol increased at the rate of 10% in pure hypercholesterolemia, 14% in mixed hyperlipidemia and 26% in pure hypertriglyceridemia after treatment for 12 weeks, but the increase rate was statistically significant only in pure hypertriglyceridemia. 6. Transient epigastric discomfort was complained by 2 patients, but subsided spontaneously with continuous treatment. 7. In view of these results, procetofene appears to be an effective and well tolerated agent for the treatment of all the types of hyperlipidemia.
Cholesterol ; Fenofibrate ; Humans ; Hypercholesterolemia ; Hyperlipidemias ; Hypertriglyceridemia ; Triglycerides

No abstract available.
Child* ; Fatty Liver ; Humans ; Hypercholesterolemia ; Incidence* ; Obesity

Hypercholesterolemia is an important modifiable risk factor for coronary heart disease. Lifestyle changes in diet and physical activity can improve cholesterol levels. This study aimed to compare the fruits and vegetables (FV) intake and physical activity (PA) between hypercholesterolemic adults and nonhypercholesterolemic adults in Malaysia, and to investigate factors associated with meeting the recommended levels of FV intake and PA in a hypercholesterolemic population. Methods: This study was based on 17,988 participants (response rate 98.7%) aged 18 years and above who responded to the hypercholesterolemia questionnaire in the 2011 Malaysian National Health and Morbidity Survey (NHMS), a cross-sectional study with two-stage stratified sampling design. Data were obtained by trained enumerators via face-to-face interviews and were analysed by descriptive analysis, chi-square test, and univariable and multivariable logistic regression. Results: Out of the total population assessed, 39.0% had hypercholesterolemia. The prevalence of consuming five or more servings of FV per day is low (7.8%) while 36.0% were physically inactive among the hypercholesterolemic adults. No significant differences were observed in FV intake and PA between hypercholesterolemic and non-hypercholesterolemic populations. Gender, age and educational levels were associated with FV intake and PA among hypercholesterolemic adults. Hypercholesterolemic adults who were underweight or obese were less likely to consume FV, while those who were former smokers and those who had diabetes and heart disease were less likely to be physically active. Conclusion: These findings are relevant for future health promotion strategies, suggesting that more intensive interventions are needed to increase FV intake and PA level in hypercholesterolemic population and in the general population.
Hypercholesterolemia ; Fruit ; Vegetables ; Eating ; Motor Activity